Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A weekly shot just changed the game for Turner syndrome treatment. The FDA has approved somapacitan-beco (Sogroya) as the first and only once-weekly, long-acting growth hormone for children aged 2.5 and older with Turner syndrome-related growth failure. The approval, backed by the phase 3 REAL8 trial, means 313 fewer injections per year compared to daily therapy.
A weekly shot just changed the game for Turner syndrome treatment. The FDA has approved somapacitan-beco (Sogroya) — a once-weekly injection — for children aged 2.5 years and older with growth failure associated with Turner syndrome. Made by Novo Nordisk, it's the first and only long-acting, once-weekly growth hormone option for this population. Turner syndrome is a chromosomal condition that causes short stature in girls, and treatment often spans years of daily injections.
The approval was supported by results from the phase 3 REAL8 study and marks Sogroya's fifth growth-related indication, joining approvals for idiopathic short stature, small for gestational age, Noonan syndrome, and growth hormone deficiency.
Key Takeaways:
Why it matters: For families navigating Turner syndrome — a condition that often comes with multiple health challenges — reducing daily injections to once a week could meaningfully improve treatment adherence and quality of life over what can be a multi-year therapy journey.